New drug duo aims to slow lung cancer in patients with specific gene mutation
NCT ID NCT07376382
First seen Feb 01, 2026 · Last updated May 14, 2026 · Updated 17 times
Summary
This study tests whether adding a new drug, SYS6010, to the standard treatment osimertinib can help people with a certain type of advanced lung cancer (EGFR-mutant NSCLC) live longer without their cancer growing. About 680 adults aged 18-75 will be split into two groups: one gets the new combo, the other gets standard care. The main goal is to see if the combo delays cancer progression.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for NSCLC are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Conditions
Explore the condition pages connected to this study.